Information

This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Confirm

Key Opinions in Medicine

  • Register
  • Login
Skip to content
  • Home
  • Issues
    • Allergy & Immunology
    • Cardiology
    • Conference
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes & Endocrinology
    • Gastroenterology
    • General Medicine
    • Haematology
    • Hepatology
    • Infectious Diseases
    • Metabolic Disorders
    • Neurology
    • Nursing
    • Obstetrics & Gynaecology
    • Oncology
    • Paediatrics
    • Psychiatry
    • Rheumatology
    • Surgery Insights
    • Urology
  • About
  • Contact
  • Register
  • Login

Figure 3

Published June 28, 2021 at 1519 × 286 in Optimizing patient selection for switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate once 3-monthly (PP3M) in schizophrenia.
← Previous

Figure 3. Schedule of follow-up visits after switching to paliperidone palmitate once 3-monthly (PP3M).

Popular Issues

Konkurrenz für den Therapiestandard

MOVICOL® (PEG3350 plus electrolytes): 20 years of evidence-based use

Register

profile Register

Sign up for free access to Wiley’s Key Opinions in Medicine to keep up to date with latest trends and key developments within your specialty area.

Share

Copyright © 2000-2025 by John Wiley & Sons, Inc., or related companies. All rights reserved.
Review our privacy policy. Cookie Preferences.
Web design and marketing agency Leamington Spa